BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Culmerciclib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Culmerciclib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06202261-9077@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Culmerciclib: Phase 1/2 readout est. (NCT06202261)
DESCRIPTION:Culmerciclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study of TQB2930 for Injection Monotherapy or Combination Therap
 y in Patients With Recurrent/Metastatic Breast Cancer\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/culmerciclib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06202261
URL:https://assetmemo.bio/drug/culmerciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05780567-9077@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Culmerciclib: Phase 3 readout est. (NCT05780567)
DESCRIPTION:Culmerciclib\, phase 3.\nStudy: Clinical Study on Adjuvant Ther
 apy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combi
 ned With Endocrine Therapy in Patients With Breast Cancer\nEstimated prima
 ry completion: December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/culmerciclib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05780567
URL:https://assetmemo.bio/drug/culmerciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745257-9077@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Culmerciclib: Phase 2 readout est. (NCT07745257)
DESCRIPTION:Culmerciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HE
 R2-Negative Metastatic Breast Cancer With Brain Metastases\nEstimated prim
 ary completion: 28 December 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/culmerciclib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07745257
URL:https://assetmemo.bio/drug/culmerciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07795424-9077@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Culmerciclib: Phase 2 readout est. (NCT07795424)
DESCRIPTION:Culmerciclib\, phase 2.\nStudy: Culmerciclib Combined With Letr
 ozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast C
 ancer\nEstimated primary completion: 30 March 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/culmerciclib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07795424
URL:https://assetmemo.bio/drug/culmerciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07616453-9077@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20280505
DTEND;VALUE=DATE:20280506
SUMMARY:Culmerciclib: Phase 2 readout est. (NCT07616453)
DESCRIPTION:Culmerciclib\, phase 2.\nStudy: Efficacy and Safety of Culmerci
 clib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy 
 for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer\nEstimate
 d primary completion: 5 May 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/culmerciclib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07616453
URL:https://assetmemo.bio/drug/culmerciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07857226-9077@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Culmerciclib: Phase 2 readout est. (NCT07857226)
DESCRIPTION:Culmerciclib\, phase 2.\nStudy: Trastuzumab/Pertuzumab With Ful
 vestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer\nEstimated prim
 ary completion: June 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/culmerciclib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07857226
URL:https://assetmemo.bio/drug/culmerciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07666555-9077@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Culmerciclib: Phase 2 readout est. (NCT07666555)
DESCRIPTION:Culmerciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib
  Rechallenge in HR-positive\, HER2-negative Breast Cancer Patients With Re
 sistance to First-line Endocrine Therapy.\nEstimated primary completion: 3
 0 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/culmerci
 clib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07666555
URL:https://assetmemo.bio/drug/culmerciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07796880-9077@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Culmerciclib: Phase 2 readout est. (NCT07796880)
DESCRIPTION:Culmerciclib\, phase 2.\nStudy: Neoadjuvant Culmerciclib Combin
 ed With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal
  Growth Factor Receptor 2-Negative Breast Cancer\nEstimated primary comple
 tion: 15 September 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/culmerciclib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07796880
URL:https://assetmemo.bio/drug/culmerciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07732491-9077@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Culmerciclib: Phase 2 readout est. (NCT07732491)
DESCRIPTION:Culmerciclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Culmerciclib in HR+/HER2+ Advanced Breast Cancer\nEstimated primary 
 completion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/culmerciclib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07732491
URL:https://assetmemo.bio/drug/culmerciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
